Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | GAA | P10253 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7299666 | 0.86 | MAPT (0.58) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL10678167 | 0.83 | MAPT (0.55) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL6571874 | 0.82 | MAPT (0.45) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL28367079 | 0.81 | MAPT (0.61) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL12126047 | 0.79 | MAPT (0.44) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL26929021 | 0.79 | MAPT (0.50) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL23587807 | 0.78 | MAPT (0.64) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL20552597 | 0.78 | MAPT (0.77) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL16671107 | 0.77 | MAPT (0.63) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL11502052 | 0.77 | GAA (0.68) | MAPTGAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0289782-A1 | Use of 2,6-dinitroanilin derivatives in hair dyeing compositions and new 2,6-dinitroanilin derivatives | Wella Aktiengesellschaft (DE) | 1988-11-09 | — | — | EP | claimed |
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-0964863-B1 | OXAZOLIDINES AS 5-HT2A-ANTAGONISTS | MERCK PATENT GMBH (DE) | 2003-05-21 | — | — | EP | disclosed |
| US-6462056-B1 | SUCH AS 3-(4-CHLOROPHENYL)-5-(4-(3-INDOLYL)-1-PIPERIDINYL-METHYL)OXAZOLIDIN-2-ONE; 5-HT2A ANTAGONISTS WITH 5-HT REUPTAKE INHIBITING, ANTIDEPRESSANT OR ANXIOLYTIC EFFECT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-0964863-A1 | OXAZOLIDINES AS 5-HT2A-ANTAGONISTS | MERCK PATENT GmbH (DE) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998038189-A1 | OXAZOLIDINES AS 5-HT2A-ANTAGONISTS | MERCK PATENT GMBH (DE) | 1998-09-03 | — | — | WO | disclosed |
| EP-0635505-B1 | 4-Aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GMBH (DE) | 1997-10-15 | — | — | EP | disclosed |
| US-5561145-A | 4-aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESHRANKTER HAFTUNG (DE) | 1996-10-01 | — | — | US | disclosed |
| EP-0635505-A1 | 4-Aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GmbH (DE) | 1995-01-25 | — | — | EP | disclosed |
| EP-0300272-B1 | OXAZOLIDINONES | MERCK PATENT GmbH (DE) | 1992-09-16 | — | — | EP | disclosed |
| US-4970217-A | NEUROLEPTIC | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-11-13 | — | — | US | disclosed |
| EP-0300272-A1 | Oxazolidinones | MERCK PATENT GmbH (DE) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | MAPT 1010/4885GAA 1552/4885ALDH1A1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.